After 20 weeks, both the primary oral and pulmonary metastases were responding to treatment, suggesting that BRAF-V600E may be a therapeutic target for ameloblastoma, and targeted drug therapy may be used for AC with BRAF-V600E mutations. This evidence concerns the gene BRAF and ameloblastoma.